Grant William Reed

Grant William Reed

Auto-generated profile, based on publicly available information

Grant William Reed

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YSYasser Sammour
Yasser Sammour
KBKinjal Banerjee
Kinjal Banerjee
AKArnav Kumar
Arnav Kumar
HLHassan Lak
Hassan Lak
SCSanchit Chawla
Sanchit Chawla
SKSamir Kapadia
Samir Kapadia
Background: The conventional method of implanting balloon-expandable SAPIEN-3 (S3) valve results in a final 70:30 or 80:20 ratio of the valve in the aorta:left ventricular outflow tract with published rates of permanent pacemaker around 10%. We sought to evaluate whether higher implantation of S3 reduces conduction abnormalities including the need for permanent pacemaker. Methods: We included consecutive patients who underwent transfemoral transcatheter aortic valve replacement using S3 between April 2015 and December 2018 and compared outcomes with typical valve deployment strategy to our more contemporary high deployment technique (HDT). We excluded patients with nontransfemoral access or valve-in-valve. Results: Among 1028 patients, HDT was performed in 406 patients (39.5%). Mean implantation depth under the noncoronary cusp was significantly smaller with HDT compared with conventional technique (1.5±1.6 versus 3.2±1.9 mm; P <0.001). Successful implantation was achieved in 100% of the patients in both groups with no cases of conversion to open heart surgery, second valve implantation within the first transcatheter aortic valve replacement, or coronary occlusion during transcatheter aortic valve replacement. One patient (0.2%) had valve embolization with HDT ( P =0.216). Thirty-day permanent pacemaker rates were lower with HDT (5.5% versus 13.1%; P <0.001), as were rates of complete heart block (3.5% versus 11.2%; P <0.001) and new-onset left bundle branch block (5.3% versus 12.2%; P <0.001). There were no differences in mild (16.5% versus 15.9%; P =0.804), or moderate-to-severe aortic regurgitation (1% versus 2.7%; P =0.081) at 1 year. HDT was associated with slightly higher 1-year mean gradients (13.1±6.2 versus 11.8±4.9 mm Hg; P =0.042) and peak gradients (25±11.9 versus 22.5±9 mm Hg; P =0.026). However, Doppler velocity index was similar (0.47±0.15 versus 0.48±0.13; P =0.772). Conclusions: Our novel technique for balloon-expandable S3 valve positioning consistently achieves higher implantation resulting in substantial reduction in conduction abnormalities and permanent pacemaker requirement after transcatheter aortic valve replacement without compromising procedural safety or valve hemodynamics. Operators should consider this as an important technique to improve patient outcomes.

1 April 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ZGZachary M. Gertz
Zachary M. Gertz
HHHoward C. Herrmann
Howard C. Herrmann
DLD. Scott Lim
D. Scott Lim
SKSaibal Kar
Saibal Kar
SKSamir R. Kapadia
Samir R. Kapadia
MMMichael J. Mack
Michael J. Mack
Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.

5 February 2015 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
GRGrant W. Reed
Grant W. Reed
AKAmit Kumar
Amit Kumar
JGJianping Guo
Jianping Guo
SASary Aranki
Sary Aranki
PSPrem Shekar
Prem Shekar
CCChristopher P. Cannon
Christopher P. Cannon
Background: Guidelines recommend delaying coronary artery bypass grafting (CABG) for 5 days after discontinuing clopidogrel. However, platelet function may recover quicker in certain individuals.Hypothesis: We hypothesized that perioperative measurement of platelet function with a point‐of‐care P2Y12 inhibitor assay could predict bleeding during CABG in patients exposed to clopidogrel.Methods: Verify Pre‐Op TIMI 45 was a prospective pilot study of 39 patients on clopidogrel who subsequently underwent CABG. Preoperative on‐treatment platelet reactivity was assessed with VerifyNow P2Y12 Reaction Units (PRU), with higher PRU indicating more reactive platelets. Outcomes were stratified by PRU quartiles, as well as prespecified cutpoints for the lowest quartile (PRU 173), a cutpoint for major bleeding determined by the Youden index using receiver operator curve analysis (PRU 207), and clopidogrel resistance (PRU 230).Results: Patients in higher PRU quartiles experienced smaller decreases in hemoglobin and hematocrit (P < 0.05 for all comparisons), less major bleeding (P = 0.021), and less major or minor bleeding (P = 0.003). Patients above the PRU 207 and 230 cutpoints had less chest‐tube output (P = 0.041 and P = 0.012, respectively), less major bleeding (P = 0.005 and P = 0.036, respectively), and less major or minor bleeding (P = 0.013 and P < 0.001, respectively). By receiver operator curve analysis, preoperative PRU ≤ 207 discriminated between patients with and without major bleeding during surgery (area under the curve: 0.76, 95% confidence interval: 0.59‐0.94, P = 0.018).Conclusions: In this pilot study, we found that point‐of‐care platelet function assessment could predict bleeding in patients recently exposed to clopidogrel undergoing CABG.

6 November 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
GRGrant W. Reed
Grant W. Reed
SHSamuel Horr
Samuel Horr
LYLaura Young
Laura Young
JCJoshua Clevenger
Joshua Clevenger
UMUmair Malik
Umair Malik
VMVenu Menon
Venu Menon
Background: The time‐sensitive hazard of perioperative cardiac troponin T (cTnT) elevation and whether long‐term mortality differs by mechanism of myocardial injury are poorly understood. Methods and Results: In this observational study of 12 882 patients who underwent noncardiac vascular surgery, patients were assessed for cTnT sampling within 96 hours postoperatively. Mortality out to 5‐years was stratified by cTnT level and mechanism of myocardial injury. During a median follow‐up of 26.9 months, there were 2149 (16.7%) deaths. By multivariable Cox proportional hazards analysis, there was a graded increase in mortality with any detectable cTnT compared to <0.01 ng/mL; cTnT 0.01 to 0.029 ng/mL hazard ratio (HR) 1.54 (95% CI 1.18–2.00, P =0.002), 0.03 to 0.099 ng/mL HR 1.86 (95% CI 1.49–2.31, P <0.001), 0.10 to 0.399 ng/mL HR 1.83 (95% CI 1.46–2.31, P <0.001), ≥0.40 ng/mL HR 2.62 (95% CI 2.06–3.32, P <0.001). Mortality for each mechanism of injury was greater than for patients with normal cTnT; baseline cTnT elevation HR 1.71 (95% CI 1.31–2.24; P <0.001), Type 2 myocardial infarction HR 1.88 (95% CI 1.57–2.24; P <0.001), Type 1 MI HR 2.56 (95% CI 2.56, 1.82–3.60; P <0.001). On Kaplan–Meier analysis, long‐term survival did not differ between mechanisms. The hazard of mortality was greatest within the first 10 months postsurgery. Consistent results were obtained in confirmatory propensity‐score matched analyses. Conclusions: Any detectable cTnT ≥0.01 ng/mL is associated with increased long‐term mortality after vascular surgery. This risk is greatest within the first 10 months postoperatively. While short‐term mortality is greatest with Type 1 myocardial infarction, long‐term mortality appears independent of the mechanism of injury.

1 October 2016 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
GRGrant W. Reed
Grant W. Reed
NSNegar Salehi
Negar Salehi
PGPejman R. Giglou
Pejman R. Giglou
RKRami Kafa
Rami Kafa
UMUmair Malik
Umair Malik
MSMehdi H. Shishehbor
Mehdi H. Shishehbor

1 November 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SKShameer Khubber
Shameer Khubber
NBNajdat Bazarbashi
Najdat Bazarbashi
DMDivyanshu Mohananey
Divyanshu Mohananey
AKAmer Kadri
Amer Kadri
MGMohamed M. Gad
Mohamed M. Gad
SKSamir R. Kapadia
Samir R. Kapadia